1 Stock That Could Soar by 175%, According to Wall Street

Core Viewpoint - Viking Therapeutics faced a challenging year with limited clinical progress and a negative market reaction to a major data readout, resulting in underperformance compared to the S&P 500. However, analysts are optimistic about the company's potential for significant upside in 2026, with an average price target of $93.39, suggesting a 175% increase from current levels [1]. Potential Catalysts - The leading candidate for Viking Therapeutics is VK2735, an investigational GLP-1 medicine for weight management, currently in a 78-week phase 3 study. Positive results from this study could lead to a substantial increase in share price [3]. - The completion of enrollment for the phase 3 trial is expected in late 2025, with full results anticipated in 2027. An interim analysis may be possible in 2026, but this remains uncertain. Additionally, a phase 1 maintenance study is being conducted to evaluate different regimens of VK2735 in patients who have already lost weight [4]. Importance of Weight Management - The ability to maintain weight loss is crucial, as many GLP-1 patients tend to regain weight. If Viking can demonstrate that VK2735, in various formulations or dosing intervals, can help sustain weight loss, it would provide a competitive edge in the market [5]. Short-Term Outlook - Achieving a 175% increase in share price within the year is considered unlikely, as the phase 1 maintenance study is focused on safety and tolerability rather than efficacy, which typically does not lead to significant stock price movements. Therefore, substantial catalysts for share price growth are expected to be delayed until next year [6][7].